Supersaturating infusional humanized anti-CD33 monoclonal antibody HuM195 in myelogenous leukemia

Clinical Cancer Research

Volumn 4, Issue 6, 1998, Pages 1421-1428

  Caron, Philip C ^a   Dumont, Larry ^b   Scheinberg, David A ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b PROTEIN DESIGN LABS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD33 ANTIGEN; MONOCLONAL ANTIBODY;

ARTICLE; BONE MARROW CELL; CYTOTOXICITY; FLOW CYTOMETRY; HALF LIFE TIME; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOGENICITY; LEUKEMIA CELL; MYELOID LEUKEMIA; PRIORITY JOURNAL; RECEPTOR AFFINITY; REMISSION; TARGET CELL;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTIGENS, CD; ANTIGENS, DIFFERENTIATION, MYELOMONOCYTIC; BLAST CRISIS; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; LEUKEMIA, MYELOCYTIC, ACUTE; LEUKEMIA, MYELOID, CHRONIC; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES;

EID: 0031749971     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Riechmann, L., Clark, M., Waldmann, H., and Winter, G. Reshaping human antibodies for therapy. Nature (Lond.), 332: 323-327, 1988.
2. Hale, G., Dyer, M. J., Clark, M. R., Phillips, J. M., Marcus, R., Riechmann, L., Winter, G., and Waldmann, H. Remission induction non-Hodgkin lymphoma with reshaped human monoclonal antibody Campath-1H. Lancet, i: 1394-1399, 1988.
3. Junghans, R. P., Waldman, T. A., Landolfi, N. F., Avdalovic, N. M., Schneider, W. P., and Queen, C. Anti-Tac-H, a humanized antibody to the interleukin receptor with new features for immunotherapy in malignant and immune disorders. Cancer Res., 50: 1495-1502, 1990.
4. Co, M. S., Deschamps, M., Whitley, R. J., and Queen, C. Humanized antibodies for antiviral therapy. Proc. Natl. Acad. Sci. USA. 88: 2869-2873, 1991.
5. Isaacs, J. D., Watts, R. A., Hazlemann, B. L., Hale, G., Keogan, M. T., Cobbold, S. P., and Waldmann, H. Humanized monoclonal antibody therapy for rheumatoid arthritis. Lancet, 340: 748-752, 1992.
6. Co, M. S., Avdalovic, N. M., Caron, P. C., Avdalovic, M. V., Scheinberg, D. A., and Queen, C. Chimeric and humanized antibodies with specificity for the CD33 antigen. J. Immunol., 148: 1149-1154, 1991.
7. Caron, P. C., Co, M. S., Bull, M. K., Avdalovic, N. M., and Scheinberg, D. A. Biological and immunological features of humanized M195 (anti-CD33) monoclonal antibodies. Cancer Res., 52: 6761-6767, 1992.
8. Caron, P. C., Jurcic, J. C., Scott, A. M., Finn, R. D., Divgi, C. R., Graham, M. C., Jureidini, I. M., Sgouros, G., Tyson, D., Old, L. J., Larson, S. M., and Scheinberg, D. A. A Phase IB trial of humanized monclonal antibody M195 (anti-CD33) in myeloid leukemia: specific targeting without immunogenicity. Blood, 83: 1760-1768, 1994.
9. Schwartz, M. A., Lovett, D., Redner, A., Finn, R. D., Graham, M., Divgi, C. R., Dantis, L., Gee, T., Andreeff, M., Old, L. J., Larson, S. M., and Scheinberg, D. A. Dose-escalation trial of M195 labeled with iodine 131 for cytoreduction and marrow ablation in relapsed and refractory myeloid leukemias. J. Clin. Oncol., 11: 294-303, 1993.
10. Jurcic, J. G., Caron, P. C., Miller, W. H., Jr., Yao, T. J., Maslak, P., Finn, R. D., Larson, S. M., Warrell, R. P., Jr., and Scheinberg, D. A. Sequential targeted therapy for relapsed acute promyelocytic leukemia with all-trans-retinoic acid and anti-CD33 monoclonal antibody M195. Leukemia (Baltimore), 9: 244-248, 1995.
11. Jurcic, J. G., Caron, P. C., Nikula, T. K., Papadopoulos, E. B., Finn, R. D., Gansow, O. A., Miller, W. H., Jr., Geerlings, M. W., Warrell, R. P., Jr., Larson, S. M., and Scheinberg, D. A. Radiolabeled anti-CD33 monoclonal antibody M195 for myeloid leukemias. Cancer Res., 55 (Suppl.): 5908s-5910s, 1995.
12. Scheinberg, D. A., Jurcic, J. G., Caron, P. C., Papadopoulos, E. B., Larson, S. M., Finn, R. D., McDevitt, M., and Sgouros, G. Radioimmunotherapy of Myeloid Leukemias with Anti-CD33 Based Agents. Proceedings of the Sixth Conference on Radioimmunodetection and Radioimmunotherapy of Cancer. 1996.
13. Jurcic, J. G., Caron, P. C., DeBlasio, A., Dumont, L., Warrell, R. P., and Scheinberg, D. A. Targeted therapy with humanized anti-CD33 monoclonal antibody (HuM195) reduces residual disease in acute promyelocytic leukemia. Blood, 86 (Suppl.): 517a, 1995.
14. Xu, Y., and Scheinberg, D. A. Elimination of human leukemia by monoclonal antibodies in an athymic nude mouse leukemia model. Clin. Cancer Res., 1: 1179-1187, 1995.
15. Stone, M. J., Sausville, E. A., Fay, J. W., Headlee, D., Collins, R. H., Figg, W. D., Stetler-Stevenson, M., Jain, V., Jaffe, E. S., Solomaon, D., Lush R. M., Senderowicz, A., Ghetie, V., Schindler, J., Uhr, J. W., and Vitetta, E. S. A Phase I study of bolus versus continuous infusion of the anti-CD 19 immunotoxin, IgG-HD37-dgA, in patients with B-cell lymphoma. Blood, 88: 1188-1197, 1996.
16. Engert, A., Diehl, V., Schnell, R., Radszuhn, A., Hatwig, M-T., Drillich, S., Schon, G., Bohlen, H., Tesch, h., Hansmann, M-L., Barth, S., Schindler, J., Ghetie, V., Uhr, J., and Vitetta, E. A Phase-I study of an anti-CD25 ricin A-chain immunotoxin (RFT5-SMPT-dgA) in patients with refractory Hodgkin's lymphoma. Blood, 89: 403-410, 1997.
17. Amlot, P., Stone, M. J., Cunningham, D., Fay, J., Newman, J., Collins, R., May, R., McCarthy, M., Richardson, J., Ghetie, V., Ramillo, O., Thorpe, P., Uhr, J., and Vitetta, E. S. A Phase-I study of an anti-CD22-deglycosylated ricin A-chain immunotoxin in the treatment of B-cell lymphomas resistant to conventional therapy. Blood, 82: 2624-2633, 1993.
18. Sausville, E. A., Headlee, D., Stetler-Stevenson, M., Jaffe, E. S., Solomon, D., Figg, W. D., Herdt, J., Kopp, W. C., Rager, H., Steinberg, S. M., Ghetie, V., Schindler, J., Uhr, J. W., Wittes, R. E., and Vitetta, E. S. Continuous infusion of the anti-CD22 immunotoxin IgG-RFB4-SMPT-dgA in patients with B-cell lymphoma: a Phase-I study. Blood, 85: 3457-3465, 1995.
19. Valone, F. H., Kaufman, P. A., Guyre, P. M., Lewis, L. D., Memoli, V., Deo, Y., Gaziano, R., Fisher, J. L., Meyer, L., Mrozek-Orlowski, M., Wardwell, K., Guyre, V., Morley, T. L., Arvizu, C., and Fanger, M. W. Phase Ia/Ib trial of bispecific antibody MDX-210 antibody with advanced breast or ovarian cancer that overexpresses the proto-oncogene HER-2/neu. J. Clin. Oncol., 13: 2281-2292, 1995.
20. Osterborg, A., Dyer, M. J. S., Bunjes, D., Pangalis, G. A., Bastion, Y., Catovsky, D., and Mellstedt, H. Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia. J. Clin. Oncol., 15: 1567-1574, 1997.
21. Winton, E. F., Srinivasiah, J., Kim, B. K., Hillyer, C. D., Strobert, E. A., Orkin, J. L., Swenson, R. B., McClure, H. M., Myers, L. A., and Saral, R. Effect of recombinant human interleukin-6 (rhIL-6) and rhIL-3 on hematopoietic regeneration as demonstrated in a nonhuman primate chemotherapy model. Blood, 84: 65-73, 1994.
22. Weber, J., Yang, J. C., Topalian, S. L., Parkinson, D. R., Schwartzentruber, D. S., Ettinghausen, S. E., Gunn, H., Mixon, A., Cole, D., Levin, R., and Rosenberg, S. A. Phase I trial of subcutaneous interleukin-6 in patients with advanced malignancies. J. Clin. Oncol., 11: 499-506, 1993.
23. Atkins, M. B., Kappler, K., Mier, J. W., Isaacs, R. E., and Berkman, E. M. Interleukin-6-associated anemia: determination of the underlying mechanism. Blood, 86: 1288-1291, 1995.
24. Freeman, S. D., Keim, S., Barber, E. K., and Crocker, P. R. Characterization of CD33 as a new member of the sialoadhesin family of cellular interaction molecules. Blood, 85: 2005-2012, 1995.
25. Caron, P. C., Lai, L. T., and Scheinberg, D. A. Interleukin-2 enhancement of cytotoxicity by humanized monoclonal antibody M195 (anti-CD33) in myelogenous leukemia. Clin. Cancer Res., 1: 63-70, 1995.
26. Weisburg, J. H., Curcio, M., Caron, P. C., Raghu, G., Mechetner, E., Roepe, P. D., and Scheinberg, D. A. The multidrug resistance phenotype confers immunological resistance. J. Exp. Med., 183: 2699-2704, 1996.
27. McGraw, K. J., Rosenblum, M. G., Cheung, L., and Scheinberg, D. A. Characterization of murine and humanized anti-CD33, gelonin immunotoxins reactive against myeloid leukemias. Cancer Immunol. Immunother., 39: 367-374, 1994.
28. Robertson, M. J., Soiffer, R. J., Freedman A. S., Rabinowe, S. L., Anderson, K. C., Ervin, T. J., Murray, C., Dear, K., Griffin, J. D., Nadler, L. M., and Ritz, J. Human bone marrow depleted of CD33-positive cells mediates delayed but durable reconstitution of hematopoiesis: clinical trial of My9 monoclonal antibody-purged autografts for the treatment of acute myeloid leukemia. Blood, 79: 2229-2236, 1992.